Markets for Pharmaceutical Products

Handbook of Health Economics

Volumn 2, Issue , 2011, Pages 763-823

  Scott Morton, Fiona ^a   Kyle, Margaret ^b  

^a YALE SCHOOL OF MANAGEMENT   (United States)

^b TOULOUSE SCHOOL OF ECONOMICS   (France)

Author keywords

Competition; Innovation; Market structure; Pharmaceuticals; Productivity; Regulation

Indexed keywords

EID: 83255192321     PISSN: 15740064     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-444-53592-4.00012-8     Document Type: Chapter

References (99)

1. Acemoglu D., Linn J. Market size in innovation: Theory and evidence from the pharmaceutical industry. Quarterly Journal of Economics 2004, 119(3):1049-1090.
2. Adams C.P., Van Brantner V. Estimating the cost of new drug development: Is it really $802 million?. Health Affairs 2006, 25(2):420-428.
3. Akerlof G.A. The market for "lemons": Quality uncertainty and the market mechanism. Quarterly Journal of Economics 1970, 84(3):488-500.
4. Allain, M.-L., Henry, E., & Kyle, M. (2011). Inefficiencies in technology transfer: Theory and empirics. CEPR Working Paper 8206.
5. Appelt, S. (2010). Authorized generic entry prior to patent expiry: Reassessing incentives for independent generic entry. SFB/TR 15 Discussion Paper 357.
6. Arora A., Fosfuri A., Gambardella A. Markets for technology: The Economics of innovation and corporate strategy 2001, MIT Press.
7. Arrow, K. (1962). Economic welfare and the allocation of resources for invention. In The rate and direction of inventive activity: Economic and social factors (pp. 609-626). National Bureau of Economic Research, Inc.
8. Azoulay P. Capturing knowledge within and across firm boundaries: Evidence from clinical development. American Economic Review 2004, 94(5):1591-1612.
9. Bell C., Griller D., Lawson J., Lovren D. Generic drug pricing and access in Canada: What are the implications? 2010, Health Council of Canada, Toronto.
10. Berndt E. Pharmaceuticals in U.S. health care: Determinants of quantity and price. Journal of Economic Perspectives 2002, 16(4):45-66.
11. Berndt, E. & Aitken, M. (2010). Brand loyalty, generic entry and price competition in pharmaceuticals in the quarter century after the 1984 Waxman-Hatch legislation, NBER Working Paper 16431.
12. Berndt, E., McGuire, T., & Newhouse, J. (2011). A primer on the economics of prescription pharmaceutical pricing in health insurance markets. NBER Working Paper 16879.
13. Berndt, E. R., Gottschalk, A. H. B., Philipson, T., & Strobeck, M. W. (2005). Assessing the impacts of the Prescription Drug User Fee Acts (PDUFA) on the FDA Approval Process. Forum for Health Economics & Policy, Vol. 8 (Frontiers in Health Policy Research), Article 2.
14. Berndt E.R., Ling D., Kyle M. The long shadow of patent expiration: Do Rx to OTC switches provide an afterlife?. Scanner data and price indexes 2003, 229-267. University of Chicago Press, Chicago. R. Feenstra, M. Matthew Shapiro (Eds.).
15. Berry S.T., Levinsohn J., Pakes A. Automobile prices in market equilibrium. Econometrica 1995, 63(4):841-890.
16. Blume-Kohout, M. E. & Sood, N. (2008). The impact of Medicare Part D on pharmaceutical research and development. NBER Working Paper 13857.
17. Brekke K.R., Holmas T.H., Straume O.R. Reference pricing, competition, and pharmaceutical expenditures: Theory and evidence from a natural experiment. Journal of Public Economics 2011, 95(7-8):624-638.
18. Chou Y.J., Yip W.C., Lee C.-H., Huang N., Sun Y.-P., Chang H.-J. Impact of separating drug prescribing and dispensing on provider behaviour: Taiwan's experience. Health Policy and Planning 2003, 18(3):316-329.
19. Cockburn I., Henderson R. Absorptive capacity, coauthoring behavior, and the organization of research in drug discovery. Journal of Industrial Economics 1998, 46(2):157-182.
20. Cockburn I., Grabowski H., Long G. The market for follow-on biologics: How will it evolve?. Health Affairs 2006, 25(5):1291-1301.
21. Cockburn I.M. Is the pharmaceutical industry in a productivity crisis?. Innovation policy and the economy 2007, Vol. 7:1-32. The MIT Press, (Chapter 1).
22. Cohen, W. M., Nelson, R. R., & Walsh, J. P. (2000). Protecting their intellectual assets: Appropriability conditions and why U.S. manufacturing firms patent (or not). NBER Working Paper No. 7552.
23. Danzon P., Chao L.-W. Cross-national price differences for pharmaceuticals: How large and why?. Journal of Health Economics 2000, 19:159-195.
24. Danzon, P. & Furukawa, M. (2003). Prices and availability of pharmaceuticals: Evidence from nine countries. Health Affairs, Jul.-Dec.(Web Exclusives), W3-521-W3-536.
25. Danzon P., Furukawa M. Prices and availability of biopharmaceuticals: An international comparison. Health Affairs 2006, 25(5):1353-1362.
26. Danzon P.M., Furukawa M.F. International prices and availability of pharmaceuticals in 2005. Health Affairs 2008, 27(1):221-233.
27. Danzon P., Pauly M. Health insurance and the growth in pharmaceutical expenditures. Journal of Law and Economics 2002, 45:587-613.
28. Danzon, P. & Pereira, N. (2011). Exits from vaccine markets in the US: The role of competition vs. regulation. Forthcoming in International Journal of the Economics of Business.
29. Danzon P., Towse A. Differential pricing for pharmaceuticals: Reconciling access, R&D, and patents. International Journal of Health Care Finance and Economics 2003, 3:183-205.
30. Danzon P., Wang Y.R., Wang L. The impact of price regulation on the launch delay of new drugs-evidence from twenty-five major markets in the 1990s. Health Economics 2005, 14(3):269-292.
31. David G., Markowitz S., Richards S. The effects of pharmaceutical marketing and promotion on adverse drug events and regulation. American Economic Journal: Economic Policy 2010, 2(4):1-25.
32. DiMasi J.A. Risks in new drug development: Approval success rates for investigational drugs. Clinical Pharmacology & Therapeutics 2001, 69:297-307.
33. DiMasi J.A., Grabowski H.G. The cost of biopharmaceutical R&D: Is biotech different?. Managerial & Decision Economics 2007, 28:469-479.
34. DiMasi J.A., Hansen R.W., Grabowski H.G. The price of innovation: New estimates of drug development costs. Journal of Health Economics 2003, 22(2):151-185.
35. Dorfman R., Steiner P.O. Optimal advertising and optimal quality. American Economic Review 1954, 44:826-836.
36. Dresser R., Frader J. Off-label prescribing: A call for heightened professional and government oversight. Journal of Law, Medicine & Ethics 2009, 37(3):476-486.
37. Dubois, P., De Mouzon, O., Scott Morton, F., & Seabright, P. (2011). Market size and pharmaceutical innovation. CEPR Discussion Paper 8367.
38. Duggan M., Scott Morton F. The distortionary effects of government procurement: Evidence from Medicaid prescription drug purchasing. Quarterly Journal of Economics 2006, 121(1):1-30.
39. Duggan M., Scott Morton F. The effect of the Medicare drug benefit on pharmaceutical prices and utilization. American Economic Review 2010, 100(1):590-607.
40. Duggan, M. & Scott Morton, F. (forthcoming 2011). The medium-term impact of Medicare Part D on pharmaceutical prices. American Economic Review Papers and Proceedings.
41. Dunn, A. (2010). Drug innovations and welfare measures computed from market demand: The case of anti-cholesterol drugs. Bureau of Economic Analysis Working Paper.
42. Ellison S.F., Snydor C. Countervailing power in wholesale pharmaceuticals. Journal of Industrial Economics 2010, 58:32-53.
43. Ellison S.F., Wolfram C. Coordinating on lower prices: Pharmaceutical pricing under political pressure. RAND Journal of Economics 2006, 37:2.
44. Ellison S.F., Cockburn I., Griliches Z., Hausman J. Characteristics of demand for pharmaceutical products: An exploration of four cephalosporins. RAND Journal of Economics 1997, 28(3):426-446.
45. Fabrizio, K. & Thomas, L. G. (2011). The impact of local demand on product innovation in a global industry. Strategic Management Journal (forthcoming).
46. Frank R.G., Salkever D.S. Generic entry and the pricing of pharmaceuticals. Journal of Economics and Management Strategy 1997, 6:75-90.
47. Furman J., Kyle M., Cockburn I., Henderson R. Public & private spillovers, location, and the productivity of pharmaceutical research. Annales d'Economie et Statistique 2005, 79/80:165-188.
48. Gagnon M.-A., Lexchin J. The cost of pushing pills: A new estimate of pharmaceutical promotion expenditures in the United States. PLoS Medicine 2008, 5(1):e1. (doi:10.1371).
49. Grabowski H., Kyle M. Mergers and alliances in pharmaceuticals: Effects on innovation and R&D productivity. The Economics of corporate governance and mergers 2008, Edward Elgar Publishing, Cheltenham, UK. K.P. Gugler, B.B. Yurtoglu (Eds.).
50. Grabowski, H., Kyle, M., Mortimer, R., Long, G., & Kirson, N. (2011). Evolution of market exclusivity. Paragraph IV Challenges and Generic Penetration.
51. Grabowski H., Ridley D.B., Schulman K.A. Entry and competition in generic biologics. Managerial and Decision Economics 2007, 28:439-451.
52. Guedj, I. & Scharfstein, D. S. (2004). Organizational scope and investment: Evidence from the drug development strategies and performance of biopharmaceutical firms. NBER Working Paper Series 10933.
53. Hellerstein J. The importance of the physician in the generic versus trade-name prescription decision. RAND Journal of Economics 1998, 29(1):108-136.
54. Hemphill, S. & Lemley, M. (2011). Earning exclusivity: Generic drug incentives and the Hatch-Waxman Act. Antitrust Law Journal (forthcoming).
55. Henderson R., Cockburn I. Scale, scope, and spillovers: The determinants of research productivity in drug discovery. RAND Journal of Economics 1996, 27(1):32-59.
56. Higgins M.J., Rodriguez D. The outsourcing of R&D through acquisitions in the pharmaceutical industry. Journal of Financial Economics 2006, 80(2):351-383.
57. Huckfeldt, P. & Knittel, C. (2010). Pharmaceutical use following generic entry: Paying and buying less. University of California at Davis Working Paper.
58. Iizuka T. Experts' agency problems: Evidence from the prescription drug market in Japan. RAND Journal of Economics 2007, 38:844-862.
59. Iizuka T., Jin G. The effects of prescription drug advertising on doctor visits. Journal of Economics & Management Strategy 2005, 14(3):701-727.
60. Jacobson M., O'Malley J., Earle C.C., Gaccione P., Pakes J., Newhouse J.P. Does reimbursement influence chemotherapy treatment for cancer patients. Health Affairs 2006, 25(2):437-443.
61. Jena A., Philipson T. Cost-effectiveness as price controls. Health Affairs 2007, 26(3):696-705.
62. Kanavos P.G., Costa-Font J. Pharmaceutical parallel trade in Europe: Stakeholder and competition effects. Economic Policy 2005, 20(44):751-798.
63. Kirsch I. The emperor's new drugs: Exploding the antidepressant myth 2009, The Bodley Head, London.
64. Kremer, M. & Snyder, C. M. (2003). Why are drugs more profitable than vaccines? NBER Working Paper No. 9833.
65. Kremer, M., Berndt, E., Glennerster, R., Lee, J., Levine, R., Weizsäcker, G., et al. (2011). Advance market commitments for vaccines against neglected diseases: Estimating costs and effectiveness. Forthcoming in Health Economics.
66. Kremer M., Glennerster R., Williams H. The price of life. Foreign Policy 2005, May/June(2005):26-27.
67. Kremer M., Glennerster R., Williams H. Creating markets for vaccines. Innovations 2006, 1(1):67-79.
68. Kyle M. Strategic responses to parallel trade. B.E. Journal of Economic Analysis and Policy: Advances 2011, 11(2). Article 2.
69. Kyle, M. & McGahan, A. (2011). Investments in pharmaceuticals before and after TRIPS. Forthcoming in Review of Economics and Statistics.
70. Kyle M., Allsbrook J., Schulman K. Does re-importation reduce price differences for prescription drugs? Lessons from the European Union. Health Services Research 2008, 43(4):1308-1324.
71. Lerner J., Merges R.P. The control of technology alliances: An empirical analysis of the biotechnology industry. Journal of Industrial Economics 1998, 46(2):125-156.
72. Lichtenberg F. Pharmaceutical innovation and the burden of disease in developing countries. Journal of Medicine and Philosophy 2005, 30:663-690.
73. Lichtenberg, F. R. & Waldfogel, J. (2003). Does misery love company? Evidence from pharmaceutical markets before and after the Orphan Drug Act. NBER Working Paper No. 9750.
74. Limbrock F. Pecuniary and non-pecuniary incentives in prescription pharmaceuticals: The case of statins. B.E. Journal of Economic Analysis & Policy (Advances). Article 1 2011, 11(2).
75. MacGarvie, M. & Koenig, P. (2011). Regulatory policy and the location of bio-pharmaceutical FDI in Europe. Boston University Working Paper.
76. Maloney M., Civan A. The determinants of pharmaceutical research and development investments, with Abdulkadir Civan. B.E. Journal of Economic Analysis & Policy: Contributions 2006, 5(1). Article 28.
77. Maloney M., Civan A. The effect of price on pharmaceutical R&D. B.E. Journal of Economic Analysis & Policy: Contributions 2009, 9(1). Article 15.
78. Maskus K., Ganslandt M. The price impact of parallel imports in pharmaceuticals: Evidence from the European Union. Journal of Health Economics 2004, 23(5):1035-1057.
79. McGuire T., Bauhoff S. Adoption of a cost-saving innovation: Germany, UK and simvastatin. England and Germany in Europe-what lessons can we learn from each other? 2011, 11-26. Nomos Verlag, Baden-Baden, Germany. N. Klusen, F. Verheyen, C. Wagner (Eds.).
80. Olson M.K. The risk we bear: The effects of review speed and industry user fees on new drug safety. Journal of Health Economics 2008, 27(2):175-200.
81. Osborn J. Can I tell you the truth? A comparative perspective on regulating off-label scientific and medical information. Yale Journal of Health Policy, Law & Ethics 2010, 10:299.
82. Pammolli F., Magazzini L., Riccaboni M. The productivity crisis in pharmaceutical R&D. Nature Reviews Drug Discovery 2011, 10:428-438.
83. Pavcnik N. Do pharmaceutical prices respond to patient out-of-pocket expenses?. RAND Journal of Economics 2002, 33(3):469-487.
84. Podolsky S.H., Greene J.A. A historical perspective of pharmaceutical promotion and physician education. JAMA: The Journal of the American Medical Association 2008, 300(7):831-833.
85. Regan T. Generic entry, price competition, and market segmentation in the prescription drug market. International Journal of Industrial Organization 2008, 26:930-948.
86. Reiffen D., Ward M.R. Generic drug industry dynamics. Review of Economics and Statistics 2005, 87(1):37-49.
87. Ridley, D. (2011). Payments, promotion and the purple pill. Duke University Working Paper.
88. Ridley D.B., Grabowski H.G., Moe J.L. Developing drugs for developing countries. Health Affairs 2006, 25(2):313-324.
89. Ridley D.B., Kramer J.M., Tilson H.H., Grabowski H.G., Schulman K.A. Spending on postapproval drug safety. Health Affairs 2006, 25(2):420-428.
90. Saito S., Mukohara K., Bito S. Japanese practicing physicians' relationships with pharmaceutical representatives: A national survey. PLoS ONE 2010, 5(8):e12193.
91. Scott Morton F.M. Entry decisions in the generic pharmaceutical industry. RAND Journal of Economics 1999, 30(3):421-440.
92. Thiers F.A., Sinskey A.J., Berndt E.R. Trends in the globalization of clinical trials. Nature Reviews Drug Discovery 2008, 7:13-14.
93. Thomas L.G. The Japanese pharmaceutical industry: The new drug lag and the failure of industrial policy 2001, Edward Elgar, Cheltenham, UK.
94. US Congress Office of Technology Assessment (1993). Pharmaceutical R&D: cost, risks, and rewards. Pub. no. OTA-H-522. Washington: US Government Printing Office.
95. Varian H. Price discrimination and social welfare. American Economic Review 1985, 75(4):870-875.
96. Waning B., Diedrichsen E., Moon S. A lifeline to treatment: The role of Indian generic manufacturers in supplying antiretroviral medicines to developing countries. Journal of the International AIDS Society 2010, 13:35.
97. Wosinska M. Direct-to-consumer advertising and drug therapy compliance. Journal of Marketing Research 2005, 42(3):323-332.
98. Yadav, P. (2010). Differential pricing for pharmaceuticals: Review of current knowledge, new findings and ideas for action. Department for International Development (DFID) Report.
99. Yin W. R&D policy, agency costs and innovation in personalized medicine. Journal of Health Economics 2009, 28(5):950-962.